Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $81.36 +2.07%
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +12.1%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $85.7 million versus the consensus estimate of $90.36 million.
GUIDANCE:
2021 revenue guidance $375 - 405 million
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
